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Aim: To evaluate, using post hoc analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon-like peptide-1 receptor
agonist, liraglutide (IDegLira), was consistently effective in patients with type 2 diabetes (T2D), regardless of the stage of T2D progression.
Methods: Using data from the DUAL I extension [insulin-naïve patients uncontrolled on oral antidiabetic drugs (OADs), n= 1660, 52weeks] and DUAL II
(patients uncontrolled on basal insulin plus OADs, n= 398, 26weeks) randomized trials, the efficacy of IDegLira was investigated with regard to measures
of disease progression stage including baseline glycated haemoglobin (HbA1c), disease duration and previous insulin dose.
Results: Across four categories of baseline HbA1c (≤7.5–9.0%), HbA1c reductions were significantly greater with IDegLira (1.1–2.5%) compared with
IDeg or liraglutide alone in DUAL I. In DUAL II, HbA1c reductions were significantly greater with IDegLira (0.9–2.5%) than with IDeg in all but the
lowest HbA1c category. In DUAL I, insulin dose and hypoglycaemia rate were lower across all baseline HbA1c categories for IDegLira versus IDeg, while
hypoglycaemia was higher with IDegLira than liraglutide, irrespective of baseline HbA1c. In DUAL II, insulin dose and hypoglycaemia rate were similar
with IDegLira and IDeg (maximum dose limited to 50 U) independent of baseline HbA1c. The reduction in HbA1c with IDegLira was independent of disease
duration and previous insulin dose but varied depending on pre-trial OAD treatment.
Conclusions: IDegLira effectively lowered HbA1c across a range of measures, implying suitability for patients with either early or advanced T2D.
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Introduction
Despite the advances in treatment for type 2 diabetes (T2D),
many patients remain in poor glycaemic control for many years
[1–3].Thismay be attributable to the complex pathophysiology
of T2Dor a combination of factors, including clinical inertia, an
actual or perceived fear of weight gain and hypoglycaemia, or a
lack of adherence to treatment [2,4–6].
IDegLira (Xultophy®) is the first fixed-ratio combination of
a basal insulin, insulin degludec (IDeg), and a glucagon-like
peptide-1 receptor analogue, liraglutide. IDegLira is adminis-
tered as a once-daily injection independently of meals or time
of day in people with T2D and is titrated in dose steps, with
each dose step containing 1U of IDeg and 0.036mg of liraglu-
tide. For patients starting IDegLira as add-on therapy to oral
antidiabetic drugs (OADs), the recommended starting dose is
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10 dose steps (10U IDeg and 0.36mg liraglutide) once daily,
while for patients switching to IDegLira from basal insulin, the
recommended starting dose is 16 dose steps (16U IDeg and
0.6mg liraglutide) once daily; the maximum dose is 50 dose
steps (50U IDeg/1.8mg liraglutide) once daily [7].
The efficacy and safety of the two components of IDegLira,
IDeg and liraglutide, have been extensively investigated in
clinical development programmes (reviewed in Bode [8],
Keating [9] and Vora et al. [10]). The IDegLira phase IIIa
programme comprised the 52-week DUAL I (26-week main
trial and 26-week extension trial) and the 26-week DUAL II
trials [11–13].
The objective of the present post hoc analyses was to deter-
mine the robustness of the efficacy results with IDegLira and its
component parts in the DUAL I and DUAL II trials as a func-
tion of three variables, which could be considered surrogates
of baseline disease severity: glycated haemoglobin (HbA1c)
level at baseline, diabetes duration and diabetes treatment at
screening.
Materials and Methods
The detailed trial designs and methods have been reported
previously [11–13]. DUAL I was a 26-week trial [12], with an
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extension to 52weeks [13], comparing IDegLira with IDeg
or liraglutide in insulin-naïve patients uncontrolled on OADs
(metformin with or without pioglitazone). Throughout the
present report, when referring to DUAL I, results from the full
52-week trial are reported. InDUAL II, IDegLira was compared
with IDeg for a treatment period of 26weeks in patients who
were previously uncontrolled on 20–40U of basal insulin plus
metformin with or without sulphonylureas or glinides; these
latter two classes were discontinued at randomization [11].
In DUAL II, IDeg was limited to a maximum dose of 50U so
that the contribution of the liraglutide component of IDegLira
could be evaluated at equivalent insulin doses. The trial pro-
tocols were approved by independent ethics committees or
institutional review boards at all participating institutions and
conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines [14,15]. Written informed
consent from all patients was obtained before enrolment. The
trials were registered at clinicaltrials.gov: NCT01336023 and
NCT01392573.
The baseline characteristics of the patients with T2D in the
two trials are summarized in Table S1.
Statistical Analysis
In the present post hoc analyses, changes in HbA1c,
end-of-trial insulin dose and confirmed hypoglycaemia
rate were assessed for each study across baseline HbA1c
categories: ≤7.5% (≤58mmol/mol); >7.5 to ≤8.5% (>58 to
≤69mmol/mol); >8.5 to ≤9.0% (>69 to ≤75mmol/mol); and
>9.0% (>77mmol/mol). Change in HbA1c was also analysed
across four body mass index (BMI) categories: <25 kg/m2
(DUAL I only), ≥25 to <30, ≥30 to <35 and ≥35 kg/m2, and
across concomitant medication (metformin vs metformin plus
other OADs). Change in HbA1c and end-of-trial insulin dose
were assessed using analysis of covariance, with treatment,
region, previous antidiabetic treatment and stratification fac-
tors (DUAL I only) as fixed factors and baseline HbA1c as
covariate. Confirmed hypoglycaemia was defined as the occur-
rence of episodes requiring assistance (severe), or episodes
in which plasma glucose concentration (determined from
self-monitored plasma glucose) was below 3.1mmol/l, irre-
spective of symptoms. For DUAL I, the number of confirmed
hypoglycaemic episodes was analysed using a negative bino-
mial regression model with a log link and the logarithm of
the exposure time as offset. The model included treatment,
region, sub-study, HbA1c stratification factors and previous
antidiabetic treatment at screening as fixed factors. The same
model was used to analyse hypoglycaemia in DUAL II, but was
not applied to the different baseline HbA1c categories, as the
difference for the whole trial was non-significant.
For each treatment group, change in HbA1c was tested for
dependence on disease duration, using a regression model
with disease duration as a covariate, to estimate whether the
coefficient was significantly different from zero. The variables
specified above were also included in the model. Changes in
HbA1c with IDegLira and the comparators were also assessed
by pre-trial therapy. In DUAL I, IDegLira was stratified into
metformin versus metformin plus pioglitazone. In DUAL II,
data were analysed according to metformin or metformin and
sulphonylurea/glinide pretreatment, and according to pre-trial
insulin dose (≤30 or >30U). For change in HbA1c and insulin
dose, missing data were imputed using last observation carried
forward.
TheHbA1c values are presented in % and inmmol/mol. Val-
ues in mmol/mol were calculated from the value expressed in
% using the International Federation of Clinical Chemistry and
Laboratory Medicine equation: HbA1c (mmol/mol)= (HbA1c
[%]− 2.15)× 10.929 [16].
Results
Change in Glycated Haemoglobin Across Different Baseline
Categories
In both trials, IDegLira effectively lowered HbA1c across
all baseline categories of HbA1c (Figure 1A, B). In DUAL I,
HbA1c reductions with IDegLira were significantly greater
versus reductions with IDeg or with liraglutide in all base-
line HbA1c categories (Figure 1A), with observed mean
reductions from baseline of 1.1–2.5% (12–27mmol/mol). In
DUAL II, HbA1c observed mean reductions were 0.9–2.5%
(10–27mmol/mol) across baseline HbA1c categories with
IDegLira, which were significantly greater versus the reduc-
tions with IDeg in all baseline HbA1c categories except for
≤7.5% (≤58mmol/mol), in which patient numbers were low
(Figure 1B). The largest reductions in HbA1c occurred in the
highest baseline HbA1c category: 2.5% (27mmol/mol) with
IDegLira in both trials (Figure 1).
In both trials, the reductions in HbA1c occurred with
IDegLira regardless of diabetes duration (Figure 2). In
DUAL I, the regression coefficients [± standard error (s.e.)]
showed that for one additional year with diabetes, the mean
HbA1c was reduced by −0.0037% (± 0.0067) for IDegLira,
0.0037% (± 0.0091) for IDeg and −0.0126% (± 0.0094) for
liraglutide (all non-significant; Figure 2A). In DUAL II,
the regression coefficients showed that for an additional
26weeks with diabetes, the mean HbA1c was reduced
by 0.0018% (± 0.0117; non-significant) for IDegLira and
−0.0227% (± 0.0114; p= 0.0487) for IDeg (max 50U;
Figure 2B).
In DUAL I, the analysis of HbA1c reduction according to
concomitant medication showed that, in the IDegLira arm,
the reduction in HbA1c was slightly greater in patients treated
with (and continuing) metformin plus pioglitazone [2.1%
(23mmol/mol)] compared with those using metformin alone
[1.8% (19mmol/mol); estimated treatment difference (ETD)
0.21% (2.3mmol/mol); p= 0.02; Table 1A]; this difference
betweenpre-trial treatmentswas not seen in the IDeg or liraglu-
tide arms. The HbA1c reductions were significantly greater
with IDegLira compared with IDeg and liraglutide in patients
in the metformin group and those in the metformin plus
pioglitazone group (p< 0.001 in all comparisons; Table 1A).
In DUAL II, ∼50% of patients in each treatment arm
were receiving metformin only pre-trial, and continued this
unchanged during the trial. The remaining 50% continued on
their pre-trial metformin and discontinued sulphonylureas or
glinides at randomization (Table S1C).The reduction inHbA1c
with IDegLira was greater in patients treated with metformin
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Figure 1. Change in glycated haemoglobin (HbA1c; y-axis) in relation to categories of baseline HbA1c (x-axis) in DUAL I (A) and DUAL II (B). Mean
HbA1c for each treatment at baseline (diamonds) and at end-of-trial (end of arrow) with extent of the reduction in HbA1c depicted by the length of the
arrow. Vertical axes showHbA1c (left axis expressed in %, right axis expressed inmmol/mol). Data are mean from observed values based on full analysis set
with last observation carried forward; p-values from analysis of covariance analysis. *p< 0.01. IDeg, insulin degludec; IDegLira, insulin degludec/liraglutide
combination; Lira, liraglutide; ns, not significant.
only [2.1% (23mmol/mol)] compared with patients treated
with metformin plus pre-trial sulphonylureas or glinides [1.7%
(19mmol/mol); ETD −0.42% (−4.6mmol/mol); p= 0.006;
Table 1B]. Similarly, with IDeg, the reduction in HbA1c was
greater in patients treated with metformin as the only pre-trial
OAD versus metformin plus pre-trial sulphonylureas or glin-
ides (Table 1B). Additionally, the HbA1c reductions were
significantly greater with IDegLira versus those with IDeg in
patients treated with metformin only, and those treated with
metformin plus sulphonylureas or glinides pre-trial (p< 0.001
for both comparisons; Table 1B).
Notably, in DUAL II, pre-trial insulin dose (≤30 or >30U)
had no effect on end-of-trial HbA1c in either of the treat-
ment arms [end-of-trial difference for IDegLira: 0.02%
(0.22mmol/mol); p= 0.91; Table 1C].
In DUAL I, the reduction of HbA1c with IDegLira was
1.8–1.9% (20–21mmol/mol) across all baseline BMI categories
[13]. In each BMI category, HbA1c decreased more with
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Figure 2. Change in glycated haemoglobin (HbA1c; y-axis) in relation to duration of diabetes (x-axis) in DUAL I (A) and DUAL II (B).The fit line for each
treatment is least squares mean.The regression analysis estimates the linear relationship between disease duration and change in HbA1c from baseline.The
regression coefficient (𝛽) is the slope of the line given by the relationship, and the reported p value corresponds to the test of whether the slope of the line is
equal to 0, indicating no relationship between the two variables. IDeg, insulin degludec; IDegLira; insulin degludec/liraglutide combination; Lira, liraglutide.
DUAL I regression coefficients (𝛽)± standard error of the mean (s.e.m.): IDegLira 0.0037± 0.0067 (p= 0.58), IDeg−0.0037± 0.0091 (p= 0.68), liraglutide
0.0126± 0.0094 (p= 0.18). DUAL II regression coefficients (𝛽)± s.e.m.: IDegLira −0.0018± 0.0117 (p= 0.88), IDeg 0.0227± 0.0114 (p= 0.0487).
IDegLira versus IDeg or liraglutide alone (all p< 0.001; Figure
S1A). In DUAL II, the reduction of HbA1c with IDegLira was
1.6–2.1% (17–23mmol/mol; Figure S1B) and was greater with
IDegLira comparedwith insulin degludec in all BMI categories.
Insulin Dose and Rate of Hypoglycaemia
In DUAL I, the mean observed insulin dose for all patients at
end-of-trial was lower with IDegLira (39U) versus IDeg (62U)
[13]. The ETD in mean daily insulin doses for IDegLira and
IDeg was −23U (−26; −20), p< 0.0001. Similarly, across all
HbA1c categories, mean insulin dose was lower with IDegLira
versus IDeg (not analysed statistically; Figure 3A).
InDUAL II, the insulin dosewas capped at 50U; therefore, as
planned, end-of-trial insulin dose was similar in the two arms
for all patients (45U in each arm, not statistically significant)
[11]. This similarity in dose was maintained across the HbA1c
baseline categories (Figure 3B).
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Table 1. Changes in glycated haemoglobin (HbA1c) by antidiabetic treatment (A, B) or by basal insulin dose (C) at screening.
(A) DUAL I: Changes in HbA1c by antidiabetic treatment at screening
Group I Group II Group I−Group II
Metformin Metformin+ pioglitazone
N
Observed change in HbA1c*, †
from baseline to EOT N
Observed change in HbA1c*, †
from baseline to EOT
Estimated difference at
EOT (95% CI) p
IDegLira 693 −1.8 (1.1)* 140 −2.1 (1.1)* 0.21 (0.03; 0.39)* 0.02
−19.7 (12.0)† −23.0 (12.0)† 2.3 (0.3; 4.3)†
IDeg 344 −1.4 (1.1)* 69 −1.6 (1.0)* 0.07 (−0.19; 0.33)* 0.59
−15.3 (12.0)† −17.5 (10.9)† 0.8 (−2.1; 3.6)†
Lira 341 −1.2 (1.2)* 73 −1.3 (1.2)* −0.01 (−0.26; 0.24)* 0.94
−13.1 (13.1)† −14.2 (13.1)† −0.11 (−2.84; 2.62)†
Between treatment differences
Estimated difference at EOT (95% CI) Estimated difference at EOT (95% CI)
IDegLira− IDeg −0.43 (−0.56; −0.30)* −0.59 (−0.87; −0.31)* <0.0001
−4.69 (−6.12; −3.28)† −6.45 (−9.51; −3.39)†
IDegLira− Lira −0.60 (−0.73; −0.47)* −0.81 (−1.08; −0.53)* <0.0001
−6.56 (−7.98; −5.14)† −8.85 (−11.80; −5.79)†
(B) DUAL II: Changes in HbA1c by antidiabetic treatment at screening
Group I Group II Group I−Group II
Basal insulin+metformin
Basal insulin+metformin with
SU or glinides
N
Observed change in HbA1c*, †
from baseline to EOT N
Observed change in HbA1c*, †
from baseline to EOT
Estimated difference
at EOT (95% CI) p
IDegLira 95 −2.1 (1.0)* 104 −1.7 (1.2)* −0.42 (−0.71; −0.12)* 0.006
−23.0 (10.9)† −18.6 (13.1)† −4.59 (−7.76; −1.31)†
IDeg 98 −1.2 (1.2)* 101 −0.6 (1.1)* −0.65 (−0.94; −0.36)* <0.0001
−13.1 (13.1)† −6.7 (12.0)† −7.10 (−10.3; −3.93)†
Between treatment differences
Estimated difference at EOT (95% CI) Estimated difference at EOT (95% CI)
IDegLira− IDeg −0.95 (−1.23; −0.66)* −1.14 (−1.43; −0.85)* <0.0001
−10.38 (−13.44; 7.21)† −12.46 (−15.63; −9.29)†
(C) DUAL II: Changes in HbA1c by basal insulin dose at screening
Group I Group II Group I−Group II
Basal insulin dose≤30U Basal insulin dose>30U
N
Observed change in HbA1c*, †
from baseline to EOT N
Observed change in HbA1c*, †
from baseline to EOT
Estimated difference
at EOT (95% CI) p
IDegLira 126 −1.9 (1.1)* 70 −1.9 (1.0)* −0.02 (−0.30; 0.26)* 0.91
−20.8 (12.0)† −20.8 (10.9)† −0.2 (−3.3; 2.8)†
IDeg 124 −0.9 (1.2)* 73 −0.9 (1.2)* −0.22 (−0.56; 0.11)* 0.19
−9.8 (13.1)† −9.8 (13.1)† −2.4 (−6.1; 1.2)†
Data are observed mean (standard deviation). Estimated treatment differences are based on analysis of covariance. CI, confidence interval; EOT, end-of-trial; IDeg, insulin
degludec; IDegLira, insulin degludec/liraglutide combination; Lira, liraglutide.
*HbA1c in %.
†HbA1c in mmol/mol.
In DUAL I, the rate of hypoglycaemia was significantly
lower with IDegLira versus IDeg for the total trial population
(Figure 4). Rates of hypoglycaemiawere numerically lowerwith
IDegLira than with IDeg in all HbA1c categories, and signifi-
cantly lower in the categories≤7.5% (≤58mmol/mol) and>8.5
to ≤9.0% (>69 to ≤75mmol/mol). The rate of hypoglycaemia
was higher with IDegLira than with liraglutide for the overall
trial population and for all HbA1c categories.
The pattern of hypoglycaemia by HbA1c category in DUAL
II is shown in Figure 4B. The rates of hypoglycaemia were
similar except for the category HbA1c >8.5 to ≤9.0% (>69 to
≤75mmol/mol), where there were a high number of events
(25 and 30 events) in 2 IDeg-treated patients. When these 2
patients were excluded, the rate of confirmed hypoglycaemia
decreased from 530 events/100 patient-years of exposure to 246
events/100 patient-years of exposure.
Discussion
These post hoc analyses of the DUAL I (26-week main trial
period+ 26-week extension trial) and DUAL II trials were
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Figure 3. Insulin dose at end-of-trial according to baseline HbA1c category in DUAL I (A) and DUAL II (B). Data are mean dose (U) from the safety
analysis set, last observation carried forward. Error bars are standard error of the mean. EOT, end-of-trial; IDeg, insulin degludec; IDegLira, insulin
degludec/liraglutide combination.
performed to determine whether the efficacy of IDegLira
versus comparators would differ across various measures of
disease progression in T2D. The results showed that patients
with values characteristic of more advanced T2D benefit from
treatment with IDegLira to the same extent as those at an ear-
lier stage of the disease. IDegLira was efficacious, with respect
to HbA1c-lowering, across all categories of baseline HbA1c up
to 10% (86mmol/mol; the HbA1c value specified as a maxi-
mum in the inclusion criteria of both studies). There was no
apparent relationship between duration of disease and efficacy
in terms of HbA1c for IDegLira, IDeg or liraglutide in DUAL I.
Similarly, inDUAL II there was no relationship between disease
duration and efficacy in terms of HbA1c with IDegLira. The
apparent declining efficacy of IDeg with increased disease
duration was probably influenced by the trial design and the
50-U dose cap in DUAL II (meaning the insulin dose was not
fully titrated). The difference in HbA1c reduction depending
on pre-trial OADs was small but significant in both trials,
both within a treatment arm and between treatment arms. In
contrast, the pre-trial insulin dose in DUAL II did not affect
the outcome. Importantly, the greater reduction in HbA1c
with IDegLira versus comparators was apparently irrespective
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Figure 4. Confirmed hypoglycaemia rate by baseline HbA1c category in DUAL I (A) and DUAL II (B). *p< 0.05; **p= 0.001; ***p< 0.0001. Confirmed
hypoglycaemia: patient requiring assistance and/or recorded plasma glucose <3.1mmol/l; rates from the safety analysis set; p-values from the full
analysis set using a negative binomial regression model. IDeg, insulin degludec; IDegLira; insulin degludec/liraglutide combination; Lira, liraglutide;
ns, not significant.
of previous OAD treatment. The greater HbA1c reductions in
DUAL II in patients receiving metformin only pre-trial versus
those receiving metformin plus sulphonylureas or glinides in
the IDegLira and IDeg arms was probably attributable to the
discontinuation of the sulphonylureas or glinides at random-
ization. It should be noted, however, that the HbA1c reductions
in this group were large, considering patients discontinued
a treatment at randomization. Additionally, IDegLira was
efficacious across all BMI categories investigated (<25 to
≥35 kg/m2) [13].
Limitations of the present analyses are that they were post
hoc and the number of patients in some categories was small. In
DUAL II, IDeg was capped at amaximumdose of 50U, and this
may have exaggerated the advantage of IDegLira with respect
to glycaemic control over continued titration of basal insulin.
Additional titration would also be expected to be associated
with a greater risk of hypoglycaemia and weight gain, as seen
during DUAL I. The number of patients in DUAL II was much
smaller than in DUAL I and the numbers in the subgroups are
consequently smaller. The analyses were also based on clinical
46 Rodbard et al. Volume 18 No. 1 January 2016
DIABETES, OBESITY AND METABOLISM original article
trials that excluded extreme phenotypes, which are difficult to
manage, e.g. patients withHbA1c values>10% (86mmol/mol),
BMI >40 kg/m2 (excluded in DUAL I) or receiving insulin
doses in excess of 40U/day (excluded in DUAL II).
The consistent finding of a high level of efficacy for patients
with a wide spectrum of baseline characteristics is reassuring
from the perspective of clinical decision-making.
In conclusion, the robustness of the efficacy of IDegLira is
independent of the variables generally regarded as indicative
of the stage of disease progression (baseline levels of HbA1c,
duration of diabetes and baseline diabetes medication) in two
different trial populations. This indicates that IDegLira is an
effective option for treatment intensification for patients inade-
quately controlled using OADs or basal insulin, irrespective of
their baseline HbA1c.
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